Does DMEPOS Accreditation Affect Price? What Suppliers Don't Tell You

Patients shopping for durable medical equipment (DME) often assume that an accredited supplier’s price is higher because of added quality or compliance costs. The reality is more nuanced. Accreditation is required for most suppliers to bill Medicare and many private insurers, but it does not directly set or cap the price a supplier charges. The gap between what patients expect and what suppliers actually disclose has become a growing point of confusion.

Recent Trends

In recent quarters, more suppliers have begun marketing their accredited status as a mark of trustworthiness. At the same time, consumer advocacy groups have pushed for clearer cost estimates before purchase, especially for high-ticket items like oxygen concentrators, power wheelchairs, and continuous positive airway pressure (CPAP) machines. This combination has put pressure on suppliers to explain whether accreditation changes the final bill — but many still don’t offer a clear breakdown.

• Accredited status is frequently listed in supplier directories and on websites, but usually without any explanation of how it affects pricing.
• Patients increasingly post price comparisons in online forums, noting that accredited suppliers can charge more or less than non-accredited ones for identical products.
• Some suppliers offer “cash” or self-pay prices that differ from insurance-negotiated rates, creating additional confusion about the accredited price versus the retail price.

Background

DMEPOS accreditation is a federal requirement for suppliers that want to bill Medicare. It is not a one-time certification; suppliers must undergo periodic audits to maintain it. Accreditation bodies review areas such as product safety, patient documentation, complaint handling, and staff training. While this process creates administrative overhead, it does not legally compel a supplier to adopt a specific fee schedule.

In practice, accreditation affects who a supplier can do business with. Medicare, Medicaid, and many commercial insurers require it for network participation. Without accreditation, a supplier may still sell equipment, but it usually cannot submit claims on a patient’s behalf. This means the practical effect of accreditation is often a matter of market access rather than price control.

Accreditation tells a patient that a supplier follows certain safety and documentation procedures. It does not tell them whether the supplier’s price is competitive or inflated.

User Concerns

Patients report several recurring concerns when comparing accredited vs. non-accredited suppliers:

• Unexplained price gaps: Charging different amounts for the same model of equipment, even when both suppliers are accredited.
• Hidden “accreditation fees”: Occasionally appearing in invoices, despite the fact that accreditation is a business expense, not a patient copay.
• Confusion about insurance rates: An in-network accredited supplier’s allowed amount can be lower than a non-accredited supplier’s cash price, but the patient may not see this until after the claim is processed.
• Lease vs. purchase: Some suppliers bundle accreditation compliance costs into monthly rental arrangements for devices like hospital beds or ventilators without itemizing the cost.

The core issue is a lack of transparency. Most suppliers do not publish a fee schedule, and patients rarely ask whether the quoted price is tied to accreditation status. That leaves room for assumption — and occasionally for overcharging.

Likely Impact

If price transparency continues to grow, the impact on the DME market could be significant:

• For patients: Greater ability to compare out-of-pocket costs, but only if suppliers standardize how they present pricing.
• For accredited suppliers: A potential competitive advantage if they proactively explain that accreditation affects coverage eligibility, not necessarily the final price.
• For non-accredited suppliers: Pressure to justify their prices without the safety or compliance assurances that accreditation provides.
• For insurers: More pressure to share allowed amounts, especially since some patients are forced to pay upfront and wait for reimbursement.

Accreditation is unlikely to become a direct driver of price ceilings in the near term. However, it may influence pricing indirectly through contract negotiations. Suppliers with strong compliance records often have an easier time negotiating preferred network status, which can lead to lower patient cost-sharing — even if the supplier’s list price is higher.

What to Watch Next

Several developments could shape how accreditation and price interact in the coming year:

• Policy updates: Watch for any CMS changes to supplier standards or fee schedule calculations that might explicitly address administrative or accreditation cost allowances.
• State-level transparency laws: Some states are considering legislation that would require DME suppliers to disclose whether accreditation affects their quoted price.
• Patient advocacy pressure: Consumer groups may push for standard “good faith estimates” that separate accreditation-related costs from product costs.
• Market competition: If large retail pharmacy chains expand their DME offerings, their scale may force smaller accredited suppliers to clarify their pricing faster.

For now, patients should treat accreditation as an important credential — not a price tag. When comparing suppliers, ask directly whether the quote includes any accreditation-related markup, whether the price is the same for cash and insurance, and whether the supplier can provide an itemized breakdown. Suppliers who can answer those questions clearly are likely to be the ones that earn trust in a more transparent market.